HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Advances in melanoma prompt re-evaluation of SLN biopsy
-
- Drug costs, poverty, inequity and loss Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves Velcade regimen for treatment-naive mantle cell lymphoma
- FDA grants ‘breakthrough’ designation for ALK-positive NSCLC therapy
- FDA grants fast track designation to NKTT120 for sickle cell disease
- FDA grants priority review to blinatumomab for ALL
- FDA grants priority review to palbociclib for advanced breast cancer
- Guideline strongly recommends hydroxyurea, transfusion therapy for sickle cell disease
- Calcium, magnesium failed to reduce oxaliplatin-induced neurotoxicity
-
- Current tobacco use linked to oral HPV-16 infection
- Novel ALK inhibitor effective for crizotinib-resistant NSCLC
- Age-restricted PSA screening could reduce preventable deaths, overdiagnosis
- Blistering sunburns in adolescence linked with 80% higher risk for melanoma
- Eclampsia, acute systemic infection increased risk for postpartum VTE
- Increased CTCs after chemotherapy associated with worse prognosis in metastatic breast cancer
- Combination regimen safe, effective in treatment-naive myeloma
- Comorbidities increased risk for death from primary myelofibrosis
-
- Diabetics’ elevated risk for pancreatic cancer persisted long after diagnosis
- Fecal immunochemical tests detected most colorectal cancers
- IBD showed link with cervical neoplasia
- Lifetime cancer risk from imaging radiation low in most pediatric heart patients
- Lung cancer screening abnormalities prompted smoking cessation
- One in four patients with head, neck cancers do not receive guideline-directed adjuvant therapy
- Researchers establish prevalence of uterine cancer at time of hysterectomy with morcellation
- Smoking habits persisted among cancer survivors
-
- TH-302 demonstrates encouraging activity in soft tissue sarcoma
- Meridian appoints medical director for thoracic oncology
- ASCO bestows Bonadonna Award
- Center names division head
- Levine Cancer Institute appoints chief of breast medical oncology
- Oncology Nursing Society appoints new CEO
- Mount Sinai names vice chairman of urology
- Nivolumab superior to chemotherapy in metastatic melanoma
-
- Social, demographic factors linked to mortality shortly after cancer surgery
- Cobimetinib plus vemurafenib extended PFS in BRAF V600-mutated metastatic melanoma
- Addition of triptorelin to chemotherapy preserved long-term ovarian function
- Bevacizumab plus second-line chemotherapy extended PFS in HER-2–negative breast cancer
- Contralateral mastectomy did not improve survival in young women
- Maintenance therapy with bevacizumab, capecitabine extended survival in HER-2–negative breast cancer
- Parental status influenced cancer care decisions
- Single-fraction radiation effective for bone metastases
-